Nanotechnology holds promise for STD drug delivery

May 03, 2009
Distribution of nanoparticles seen by fluorescence throughout mouse reproductive tract. Credit: Woodrow/Yale

Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs — small interfering RNA (siRNA) molecules that silence genes — the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

" is a promising approach for prevention and treatment of human disease," said lead author Kim Woodrow, Yale postdoctoral fellow in Yale's School of Engineering & Applied Science. "We wanted to develop a new strategy of delivering siRNAs with a FDA-approved material."

As their name suggests, siRNAs interfere and knock out the function of in higher organism as well as in microbes that may cause STDs. The researchers designed siRNAs to target a gene expressed widely in the lining of the female mouse reproductive tract, in this proof-of-principle work.

Using densely-loaded nanoparticles made of a biodegradable polymer known as PLGA, the researchers created a stable "time release" vehicle for delivery of siRNAs to sensitive mucosal tissue like that of the female reproductive system.

They found that the particles, loaded with the drug agent, moved effectively in two important ways, penetrating to reach cells below the surface of the mucosa and distributing throughout the vaginal, cervical, and uterine regions. Furthermore, the siRNAs stayed in the tissues for at least a week and knockdown of gene activity lasted up to 14 days.

While past work has focused on delivery of siRNAs with liposomes, bubble-like carriers made of phospholipids similar to those found in cell membranes, liposomes are potentially more toxic to the mucosal tissues and are unable to provide sustained release. In the current work, the researchers demonstrated that PLGA nanoparticles were safer than the best current lipid vehicles.

Gene interference therapy is moving rapidly from basic research to application. The PLGA packaging these researchers chose is already approved as safe and non-toxic by the FDA, speeding the path to clinical trials for infectious agents such as HPV and HIV.

"Before human clinical testing can begin, our next step in research will be to test this approach directly in disease models - for example in the HIV model mice that have an immune system genetically identical to humans," said senior author W. Mark Saltzman, the Goizueta Foundation Professor of Biomedical Engineering & Chemical Engineering.

This approach holds promise for global health and the ability of people to self-apply antimicrobial treatments. Woodrow said, "It is safe and effective and much easier than getting an injection of vaccine."

More information: , advance online publication May 4, 2009.

Source: Yale University (news : web)

Explore further: Graphene imperfections key to creating hypersensitive 'electronic nose'

add to favorites email to friend print save as pdf

Related Stories

'Silencing' HIV with small bits of RNA

Aug 07, 2008

Researchers have shown that they can effectively tackle HIV-1 with small bits of gene-silencing RNA by delivering them directly to infected T cells, the major targets of the virus. While earlier studies had shown such a strategy ...

Team develops safe, effective RNA interference technique

Apr 28, 2008

A team of researchers from MIT and Alnylam Pharmaceuticals has developed safe and effective methods to perform RNA interference, a therapy that holds great promise for treating a variety of diseases including ...

Physician revolutionizes gene research

Mar 26, 2008

A dramatic new study published in the most recent issue of Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to dia ...

Team demos safety of RNA therapy

Sep 26, 2007

Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.

Recommended for you

Engineered proteins stick like glue—even in water

Sep 21, 2014

Shellfish such as mussels and barnacles secrete very sticky proteins that help them cling to rocks or ship hulls, even underwater. Inspired by these natural adhesives, a team of MIT engineers has designed ...

Smallest possible diamonds form ultra-thin nanothreads

Sep 21, 2014

For the first time, scientists have discovered how to produce ultra-thin "diamond nanothreads" that promise extraordinary properties, including strength and stiffness greater than that of today's strongest ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

stdsgirl
not rated yet May 04, 2009
April is STD awareness month, be careful. STD cases on the rise!
A friend of mine who works for the largest STD dating == Positivefish. com == told me that the new subscribers have increased 30% over 2008. Rising STD rate sparks online dating sites.